With a long scientific background in bone disease, Dr Claus Christiansen and Dr Bente Juel Riis founded Osteometer A/S in 1989, a company that developed and produced medical equipment for measuring bone mineral density.
In 1991, the company was expanded with a laboratory division to develop biochemical diagnostic assays which would later become Nordic Bioscience A/S. In 1996, it was decided to sell the medical equipment division and Nordic Bioscience continued as an independent company in new premises in Herlev in the Greater Copenhagen area.
The first biochemical marker developed by Nordic Bioscience was serum osteocalcin, a marker of bone formation. Later came urinary and serum CTX-I, a marker for bone resorption. These initial biomarkers were followed by the development of a large spectrum of novel biomarkers in several different diseases. We are now involved in many different areas, and have 70+ proprietary biomarkers in our portfolio, of which 3 are FDA validated. We have published more than 500 publications in total, and continue to produce +50 articles every year, that are published in peer-reviewed journals. Over the years, work was specialized in two divisions; the Research & Development Division now concentrating their efforts on identification of biomarkers of interest and research and development of highly specialized assays - while the other division, the laboratory performs quality assurance on the assays, up-scales the production of the assays and measures research samples in a controlled CAP-accredited environment for clients all around the world.
